Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
GRM3	2913	CHEMBL34453	CHEMBL34453	agonist	GuideToPharmacologyInteractions
GRM3	2913	CHEMBL1629855	CHEMBL1629855	allosteric modulator	GuideToPharmacologyInteractions
GRM3	2913	POMAGLUMETAD METHIONIL	CHEMBL2110730	agonist	TdgClinicalTrial, ChemblInteractions
GRM3	2913	DECOGLURANT	CHEMBL3301593	modulator	ChemblInteractions
GRM3	2913	LY2969822	CHEMBL3545270	agonist	ChemblInteractions
GRM3	2913	CHEMBL40086	CHEMBL40086	agonist	GuideToPharmacologyInteractions
GRM3	2913	CHEMBL284193	CHEMBL284193	agonist	GuideToPharmacologyInteractions
GRM3	2913	EGLUMEGAD	CHEMBL2106523	agonist	GuideToPharmacologyInteractions
GRM3	2913	CHEMBL299683	CHEMBL299683	antagonist	GuideToPharmacologyInteractions
GRM3	2913	EGLUMETAD	CHEMBL8759	agonist	TTD
GRM3	2913	LY404039	CHEMBL375611	agonist	ChemblInteractions, TTD
GRM3	2913	LY-379268	CHEMBL275079	agonist	GuideToPharmacologyInteractions
GRM3	2913	ISOSPAGLUMIC ACID	CHEMBL1329032	agonist	GuideToPharmacologyInteractions
GRM3	2913	CHEMBL432038	CHEMBL432038	antagonist	GuideToPharmacologyInteractions
GRM3	2913	RISPERIDONE	CHEMBL85		PharmGKB

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
GRM3	rs724226	G	risperidone	efficacy	yes		Allele G is associated with increased response to risperidone in people with Schizophrenia.	19451915	699638922
GRM3	rs6465084	AA	antipsychotics	toxicity	yes	Those with the AA genotype had reduced negative symptom severity (according to Brief Psychiatric Rating Scale (BPRS) negative symptoms subscale) as compared to those with the AG or GG genotype (who had minimal change or worsening in negative symptoms). Significant after correction for multiple comparisons.	Genotype AA is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotypes AG + GG.	25096017	1446908024
GRM3	rs1468412	AA + AT	antipsychotics	efficacy	yes	When combined with rs165854 AG and GG genotypes. rs165854 AG+GG/rs1468412 AA+AT was associated with a significantly increased likelihood of patients having an incomplete antipsychotic response within a cohort of 1) all patients, 2) patients receiving atypical monotherapy and 3) patients receiving risperidone. Response assessed using CGI scale, patients were either complete responders (CR) or incomplete responders (IR) based on this scale.	Genotypes AA + AT is associated with decreased response to antipsychotics in people with Schizophrenia.	25209194	1446895666
GRM3	rs2299214	CC + CT	risperidone	efficacy	yes	Only in patients who were in the "high severity group" based on baseline severity score, using clinical global impressions (CGI) score. Response assessed using CGI scale, patients were either complete responders (CR) or incomplete responders (IR) based on this scale. Those with the CC or CT genotype were more prevalent in the IR group. Note that this association did not withstand correction for multiple testing.	Genotypes CC + CT is associated with decreased response to risperidone in people with Schizophrenia as compared to genotype TT.	25209194	1446895600
GRM3	rs2299214	CC	antipsychotics	efficacy	yes	Only in patients who were in the "low severity group" based on baseline severity score, using clinical global impressions (CGI) score. Within a cohort of 1) all patients, 2) patients receiving atypical monotherapy and 3) patients receiving risperidone. Response assessed using CGI scale, patients were either complete responders (CR) or incomplete responders (IR) based on this scale. Those with the CC genotype were more prevalent in the CR group in all three cohorts. Note that this association did not withstand correction for multiple testing.	Genotype CC is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotypes CT + TT.	25209194	1446895561
GRM3	rs6465084	AG + GG	antipsychotics	efficacy	yes	Only in patients who were in the "low severity group" based on baseline severity score, using clinical global impressions (CGI) score. Within a cohort of 1) all patients, 2) patients receiving atypical monotherapy and 3) patients receiving risperidone. Response assessed using CGI scale, patients were either complete responders (CR) or incomplete responders (IR) based on this scale. Those with the AA and AG genotype were more prevalent in the CR group in all three cohorts. Note that this association did not withstand correction for multiple testing.	Genotypes AG + GG is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype AA.	25209194	1446895571